Indication

Postmenopausal osteoporosis

Postmenopausal osteoporosis is a systemic skeletal disorder that affects females following the cessation of ovarian function. Read more about Postmenopausal osteoporosis

91 drugs 59 manufacturers

Advertisement

Drugs that treat it

Common Postmenopausal osteoporosis therapies.

Showing 10–18 of 91 drugs

Filter & compare in the drug finder →Opens the drug finder with Postmenopausal osteoporosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Postmenopausal osteoporosis.

Postmenopausal osteoporosis is a systemic skeletal disorder that affects females following the cessation of ovarian function.

It is characterized by low bone mineral density and the microarchitectural deterioration of bone tissue, driven primarily by estrogen deficiency that accelerates osteoclast-mediated bone resorption beyond the compensatory capacity of osteoblastic bone formation.

This progressive uncoupling of bone remodeling leads to structural fragility and a substantially heightened susceptibility to low-trauma or fragility fractures, most commonly involving the vertebrae, hip, and distal radius.

Personalize your experience

Follow Postmenopausal osteoporosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it